The triptan drug class dominates the prescription acute treatment migraine market, particularly now that the class is almost fully generic. Despite the array of approved treatment options, new therapies have launched over the past few years that provide incremental advantages over the standard of care, and novel agents appear on the horizon. This content explores how new therapies have fared in this highly generic market and provides important context for new players entering a large, still underserved, and commercially-promising arena.


  • What patient share do key therapies and brands garner by line of therapy in the acute treatment of newly diagnosed migraine patients? What are the quarterly trends in the prescribing of acute treatments among recently-treated and newly diagnosed migraine patients?
  • How have therapies for the acute treatment of migraine been integrated into the treatment algorithm?
  • What proportion of migraineurs receive prescription drug acute therapy within two years of diagnosis, and how quickly? What percentage of patients progress to later lines of acute treatment within two years of diagnosis?
  • What percentage of migraine patients are treated with acute treatment monotherapy versus combination therapy? What are the most widely used combination therapies
  • What are the product-level compliance and persistency rates among migraine patients treated with prescription acute therapies?


Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world data patient-level claims data so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.

Related Reports

Migraine - Unmet Need - Detailed, Expanded Analysis Acute Migraine

A range of oral and nonoral triptans (e.g., sumatriptan) are available for the acute treatment of migraine and are entrenched in medical practice. However, triptans have noted clinical shortcomings...

View Details

Migraine - Geographic Focus - China - Migraine | China In-Depth | China

Migraine presents a major public health burden in China, leading to impaired quality of life, widespread health loss, and loss of productivity for a sizeable population. Owing to migraine’s n...

View Details

Migraine - Access & Reimbursement - Detailed, Expanded Analysis (US) - Acute Migraine

2020 will be a turning point for the U.S. acute migraine market. Three novel therapies—Allergan’s Ubrelvy, Eli Lilly’s Reyvow, and Biohaven’s Nurtec

View Details

Migraine - Landscape & Forecast - Disease Landscape & Forecast

The market for prescription migraine therapies comprises an array of prescription acute and prophylactic treatments and fosters a large and dynamic pipeline. In the acute space, we anticipate the l...

View Details